L. Powell

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Lawrie W. Powell, L. Powell, Lawrie W Powell, Lawrie Powell, L. W. Powell, L W Powell, Lawrie William Powell, L W. Powell, L Powell, L.w. Powell
Publication record
392 papers · 10,678 citations · H-index 51

PAPERS

Utility and limitations of Hepascore and transient elastography to detect advanced hepatic fibrosis in HFE hemochromatosis
202110 citationsauthor #11
Utility of Serum Biomarker Indices for Staging of Hepatic Fibrosis Before and After Venesection in Patients With Hemochromatosis Caused by Variants in HFE.
202023 citationsauthor #2
Regression of Fibrosis Stage With Treatment Reduces Long-Term Risk of Liver Cancer in Patients With Hemochromatosis Caused by Mutation in HFE.
202040 citationsauthor #12
PS-096-Validation study of the impact of hepatic iron concentration on the development of advanced hepatic fibrosis in HFE hemochromatosis
20190 citationsauthor #2
Detection of HFE Haemochromatosis in the clinic and community using standard erythrocyte tests.
201912 citationsauthor #6
Utility of hepatic or total body iron burden in the assessment of advanced hepatic fibrosis in HFE hemochromatosis
201913 citationsauthor #2
Phenotypic analysis of hemochromatosis subtypes reveals variations in severity of iron overload and clinical disease.
201852 citationsauthor #7
Hemochromatosis and Other Diseases Associated with Iron Overload
20180 citationsauthor #2
Haemochromatosis: a clinical update for the practising physician
201833 citationsauthor #3
Regression of fibrosis stage after treatment in patients with HFE haemochromatosis and severe fibrosis at diagnosis: relevance to hepatocellular carcinoma
20180 citationsauthor #11
Association of GNPAT p.D519G with Higher Iron Phenotypes in Women with HFE p.C282Y Homozygosity
20170 citationsauthor #11
INDEPENDENT RISK FACTORS FOR BIOPSY-PROVEN CIRRHOSIS IN HEMOCHROMATOSIS: A STUDY OF 110 HFE p.C282Y HOMOZYGOTES WITH GNPAT p.D519G GENOPTYING
20170 citationsauthor #6
INDEPENDENT ASSOCIATION OF GNPAT p.D519G WITH MARKEDLY INCREASED IRON STORES IN HFE p.C282Y HOMOZYGOTES
20170 citationsauthor #10
Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial.
201746 citationsauthor #16
HFE p.C282Y homozygosity predisposes to rapid serum ferritin rise after menopause: A genotype‐stratified cohort study of hemochromatosis in Australian women
201726 citationsauthor #11
Non-Hfe Haemochromatosis: a Phenotypic and Clinical Analysis of Published Cases and Comparison with Hfe-Haemochromatosis
20170 citationsauthor #7
Management of human factors engineering-associated hemochromatosis: A 2015 update.
20165 citationsauthor #2
Reply
20160 citationsauthor #8
Differences in Clinical Manifestations of Hemochromatosis in Hfe C282Y Homozygotes with Extreme High and Low Iron Phenotypes
20160 citationsauthor #2
GNPAT p.D519G is independently associated with markedly increased iron stores in HFE p.C282Y homozygotes.
201614 citationsauthor #10
Reply to: GNPAT variant is associated with iron phenotype in healthy Taiwanese women: A population without the HFE C282Y mutation
20160 citationsauthor #9
Reply
20160 citationsauthor #9
Reply to HEP 16‐0784.R1 and HEP 16‐0898
20161 citationsauthor #8
Exome Sequencing in Hfe C282Y Homozygotes with Extreme Hepatic Iron Overload Reveals Modifying Genes for the Development of Cirrhosis
20160 citationsauthor #5
Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron)
201514 citationsauthor #17
Reply
20150 citationsauthor #7
Table 2. [Selected HFE Pathogenic Allelic Variants].
20150 citationsauthor #2
Figure 2. [Use of serum ferritin concentration to help direct management].
20150 citationsauthor #2
GNPAT Variant Associated With Severe Iron Overload in HFE Hemochromatosis Reply
20150 citationsauthor #7
Study Site Differences in GNPAT p.D519G (rs11558492) Allele Frequencies in Men with HFE Homozygosity
20150 citationsauthor #8
Figure 1. [Algorithm for screening for HFE-associated...].
20150 citationsauthor #2
Table 1. [Summary of Molecular Genetic Testing Used in HFE-HH].
20150 citationsauthor #2
Recent advances in hemochromatosis: a 2015 update
201525 citationsauthor #3
Reply: To PMID 25605615.
20154 citationsauthor #7
Reduced mortality due to phlebotomy in moderately iron-loaded HFE haemochromatosis? The need for clinical trials.
20157 citationsauthor #9
Diabetes and hemochromatosis
20140 citationsauthor #3
Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation
2014350 citationsauthor #2
Exome Sequencing Identifies a GNPAT Variant Associated with Severe Iron Overload in HFE C282Y Homozygous Men with Extreme Phenotypes; Possible Role in Regulation of Hepcidin Expression
20141 citationsauthor #9
Exome Sequencing Identifies Genes and Variant Alleles Associated With Severity Of Iron Overload In Hemochromatosis HFE C282Y Homozygotes
20131 citationsauthor #7
IDENTIFICATION OF GENES AND VARIANT ALLELES ASSOCIATED WITH IRON OVERLOAD IN HEMOCHROMATOSIS HFE C282Y HOMOZYGOTES
20130 citationsauthor #7
Transforming growth factor-β and toll-like receptor-4 polymorphisms are not associated with fibrosis in haemochromatosis.
20132 citationsauthor #2
Honorary chief editor
20130 citationsauthor #31
Liver Disease
20120 citationsauthor #2
Management of the Patient with Ascites
20120 citationsauthor #2
Non-alcoholic fatty liver disease: is iron relevant?
201140 citationsauthor #2
Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
2011746 citationsauthor #4
Anti-mitochondrial antibodies: what’s new?
20110 citationsauthor #6
Clinical expression of HFE-associated haemochromatosis in subjects under 40 years of age
20100 citationsauthor #5
The diagnosis and management of hereditary haemochromatosis.
201011 citationsauthor #3
HFE C 282 Y Homozygotes Are at Increased Risk of Breast and Colorectal Cancer
201013 citationsauthor #11
A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE-Related Hereditary Hemochromatosis
2010120 citationsauthor #11
A Phase I/II, Open-Label, Dose-Escalation Trial of Once-Daily Oral Chelator Deferasirox to Treat Iron Overload in HFE-Related Hereditary Hemochromatosis: Final Results of the Core Study.
20096 citationsauthor #5
Overview: Liver disease and transplantation
20092 citationsauthor #1
The global burden of iron overload
200946 citationsauthor #3
187 A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION TRIAL USING THE ONCE-DAILY ORAL CHELATOR DEFERASIROX TO TREAT IRON OVERLOAD IN HFE-RELATED HEREDITARY HEMOCHROMATOSIS: FINAL RESULTS
20098 citationsauthor #11
How much iron is too much?
20087 citationsauthor #5
ANNALS OF THE RHEUMATIC DISEASES the effect of allopurinol on hepatic iron storage in rats , and
20080 citationsauthor #1
Catheter Ablation in Patients with ICDs
20080 citationsauthor #3
HFE-COMPOUND HETEROZYGOTES WITH SERUM FERRITIN < 1000 UG/L AT AGE 65 ARE NOT AT INCREASED RISK OF HEMOCHROMATOSIS COMPARED TO HFE WILD-TYPE CONTROLS
20080 citationsauthor #13
982 PHLEBOTOMY IS ASSOCIATED WITH AN IMPROVEMENT IN LIVER ENZYMES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND INCREASED HEPATIC IRON STORES
20080 citationsauthor #3
Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis.
200899 citationsauthor #2
Iron-overload-related disease in HFE hereditary hemochromatosis.
2008648 citationsauthor #17
Changing concepts in haemochromatosis families was emphasized in the Brisbane studies of Harris
20081 citationsauthor #1
Healthiron: a longitudinal population study defining the burden of disease in HFE-associated hereditary hemochromatosis
20072 citationsauthor #18
Workplace-Based Genetic Screening for the Prevention of HFE-Associated Hereditary Haemochromatosis: An Exploratory Cost-Effectiveness Analysis
20070 citationsauthor #6
Homozygosity for the C282Y mutation in the HFE gene is associated with increased risk of colorectailand breast cancer in Australian population
20073 citationsauthor #14
John Howard Tyrer CBE, MD, FRCP(Lond), FRCP(Edin), FRACP
20060 citationsauthor #1
Liver Function Tests in Abnormal Laboratory Results
20060 citationsauthor #1
The clinical relevance of compound heterozygosity for the haemochromatosis mutations (C282Y/H63D)
20060 citationsauthor #10
The effect of steatosis on iron homeostasis in HuH-7 hepatoma cells
20060 citationsauthor #7
Steatosis is a cofactor in liver injury in hemochromatosis.
2005170 citationsauthor #8
Hemojuvelin (HJV)-associated hemochromatosis: analysis of HJV and HFE mutations and iron overload in three families.
200529 citationsauthor #5
Expression of the iron regulatory peptide hepcidin is reduced in patients with chronic liver disease
20051 citationsauthor #9
HbO-Arab mutation originated in the Pomak population of Greek Thrace
20051 citationsauthor #2
Psychological Adjustment and Knowledge About Hereditary Hemochromatosis in a Clinic-Based Sample: A Prospective Study
200521 citationsauthor #4
Role of early case detection by screening relatives of patients with HFE-associated hereditary haemochromatosis.
200527 citationsauthor #1
Clinical aspects of hemochromatosis.
200584 citationsauthor #2
Treatment of Burkitt lymphoma: A single institution's experience
20050 citationsauthor #10
Hepatic fibrosis but not cirrhosis in hemochromatosis is reversed by iron removal by phlebotomy therapy.
20052 citationsauthor #1
Hereditary Hemochromatosis Genetic Testing of At-Risk Children: What Is the Appropriate Age?
200429 citationsauthor #2
The penetrance of HFE-associated hemochromatosis as assessed by clinical evaluation and liver biopsy in subjects identified by health checks, family screening or population screening
20042 citationsauthor #1
Increased duodenal expression of divalent metal transporter 1 and iron‐regulated gene 1 in cirrhosis
200419 citationsauthor #5
Idiopathic hemochromatosis: demonstration of homozygous-heterozygous mating by HLA typing of families
20048 citationsauthor #5
Kunio Okuda 21 May 1921 – 2 February 2003
20030 citationsauthor #2
Duodenal expression of iron transport molecules in untreated haemochromatosis subjects
200361 citationsauthor #4
Evidence for a sub-morphological inflammatory process in the liver in haemochromatosis.
200335 citationsauthor #5
Relative importance of female‐specific and non‐female‐specific effects on variation in iron stores between women
200370 citationsauthor #4
Asian Pacific Association for Study of the Liver (APASL)
20036 citationsauthor #61
A novel mutation in ferroportin1 is associated with haemochromatosis in a Solomon Islands patient
200383 citationsauthor #8
Hemochromatosis and alcoholic liver disease.
200389 citationsauthor #2
1059 The clinical relevance of compound heterozygosity for the hemochromatosis mutations (C282Y/H63D)
20032 citationsauthor #11
1056 Rats of iron accumulation in untreated subjects homozygous for the C282Y hemochromatosis mutation: relevance to disease penetrance
20031 citationsauthor #1
Duodenal expression of iron transport genes in untreated hemochromatosis subjects.
20020 citationsauthor #4
Hereditary hemochromatosis and liver transplantation: Implications for patient survival, graft function and the pathogenesis of hereditary hemochromatosis.
20022 citationsauthor #9
Bridging the gap between basic science and clinical medicine: mentors and memories
20024 citationsauthor #1
Book Review Proteins of Iron Metabolism Edited by Ugo Testa. 559 pp., illustrated. Boca Raton, Fla., CRC Press, 2002. $199.95. 0-8493-8676-4
20021 citationsauthor #1
Diagnosis of hemochromatosis.
200236 citationsauthor #1
A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation.
2002256 citationsauthor #2
HFE and Non-HFE Hemochromatosis
200219 citationsauthor #2
Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis.
2002275 citationsauthor #4

TIMELINE

1953 29 citations

1954 3 citations

1956 3 citations

1957 12 citations

1958 32 citations

1962 1 citations

1964 19 citations

1965 62 citations

1966 62 citations

1967 224 citations

1968 29 citations

1969 59 citations

1970 203 citations

1971 1 citations

1972 215 citations

1973 71 citations

1974 85 citations

1975 325 citations

1976 327 citations

1977 90 citations

1978 153 citations

1979 468 citations

1980 180 citations

1981 89 citations

1982 82 citations

1983 127 citations

1984 285 citations

1985 461 citations

1986 209 citations

1987 41 citations

1988 101 citations

1989 171 citations

1990 391 citations

1991 56 citations

1992 118 citations

1993 462 citations

1994 410 citations

1995 189 citations

1996 92 citations

1997 254 citations

1998 228 citations

1999 94 citations

2000 49 citations

2001 174 citations

2002 775 citations

2003 347 citations

2004 58 citations

2005 335 citations

2006 0 citations

2007 5 citations

2008 755 citations

2009 62 citations

2010 144 citations

2011 786 citations

2012 0 citations

2013 3 citations

2014 351 citations

2015 50 citations

2016 20 citations

2017 72 citations

2018 85 citations

2019 25 citations

2020 63 citations

2021 10 citations

Unknown 2 citations

L. Powell

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT